Page 4 - Regulating Stem Cells News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hemostemix Inc.: Hemostemix Announces Warrant Repricing and Extension Calgary, Alberta--(Newsfile Corp. - July 5, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce, subject to TSX Venture Exchange Approval, that it has extended for two years and repriced to $0.55 from $1, subject to the accelerator provisions stated below on all repriced warrants, 1,332,500 Warrants expiring July 9, 2021; extended 918,450 Warrants expiring November 24, 2021 of which 510,295 Warrants are repriced to $0.55 (408,155 Warrants held by insiders not...

Hemostemix Inc.: Hemostemix to Present at the Emerging Growth Conference Hemostemix" or the " Company") is pleased to announce that it will present live at the Emerging Growth Conference on May 26, 2021 from 3:30 - 4:00 ET and it invites shareholders, individual and institutional investors, as well as advisors and analysts to attend its real-time, interactive presentation. Attendees are invited to register here to ensure you are able to attend the conference and receive any updates that are released. ABOUT EMERGING GROWHT CONFERENCE The Emerging Growth conference is an effective way for pub...

Hemostemix Inc.: Hemostemix Announces Closing of Unit Private Placement Hemostemix" or the " Units") announced on April 9, 2021, for gross proceeds of $440,031.90 (the " Offering"). The Offering consisted of the issuance of an aggregate of 1,257,234 Units at a price of $0.35 per Unit. Each Unit consists of one common share in the capital of the Company (" Common Share") and one transferable common share purchase warrant (" Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.40 per Common Share for a period of 24 months from the closing of the Of...

Hemostemix Inc.: Hemostemix Announces Warrant Repricing and Extension Hemostemix" or the " Company") is pleased to announce that it has, subject to TSX Venture Exchange Approval, repriced to $0.55 each, and extended the exercise period for two years, the Warrants expiring May 7, 2020 and May 28, 2020, subject to the accelerator provisions, such that the exercise period of Warrants will be reduced to thirty (30) days, if, for any ten consecutive trading days during the unexpired term of the Warrants, the weighted average closing price of the Company's listed shares achieves or exceeds the pric...

Calgary, Alberta--(Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, with the last patient follow up